SUO 2017: Cost Effective Analysis of Neoadjuvant Chemotherapy Prior to Radical Cystectomy in T2 Bladder Cancer
Washington, DC (UroToday.com) Dr. Hamilton and colleagues presented results of their decision analysis for neoadjuvant chemotherapy prior to radical cystectomy (RC) for T2 bladder cancer. Although there is level 1 evidence  and a comprehensive meta-analysis supporting a 5% overall survival benefit for neoadjuvant chemotherapy in bladder cancer , the cost effectiveness of this strategy is still debated. The objective of this study was to present a cost effectiveness analysis of neoadjuvant chemotherapy prior to RC in the setting of T2 bladder cancer.
SUO 2017: A Nationwide Analysis of Complete Urinary Tract Extirpation
Washington, DC (UroToday.com) Dr. Jipp and colleagues assessed a nationwide analysis of complete urinary tract extirpation. Indications for complete urinary tract extirpation (bilateral nephroureterectomy and radical cystectomy) include concomitant upper and lower tract urothelial carcinoma or patients with chronic renal failure and urothelial carcinoma. Given the rarity of this operation, descriptions of complete urinary tract extirpation are limited to case reports and small case series. The objective of this study was to use a population-based database to assess long-term outcomes following complete urinary tract extirpation.
SUO 2017: Comparing Effective Treatment Strategies for Squamous Cell Carcinoma of the Bladder
Washington, DC (UroToday.com) Dr. Stensland and colleagues presented their work assessing comparative effectiveness of treatment strategies for squamous cell carcinoma of the bladder. Because treatment recommendations for muscle invasive bladder cancer (MIBC) are primarily based on urothelial carcinoma histology, the effectiveness of treatment strategies for variant histologies has been understudied. The objective of this study was to assess the effectiveness of primary treatment strategies for squamous cell carcinoma.
SUO 2017: Mutations And Gene Expression Differences Between African Americans And Non-African Americans With Urothelial Cell Carcinoma
Washington, DC (UroToday.com) While race has been established as a strong predictor in many malignancies, including prostate cancer, there is little evidence in bladder cancer. While African American’s with bladder cancer have been shown to have worse disease specific and overall survival, several factors such as socioeconomic status, access to care, and stage at presentation have been proposed as confounding variables; it remains unclear why this difference exists. However, part of the problem lies in the lack of large studies assessing non-Caucasian patients. Hence, any large series of non-Caucasian patients carries significant value.
SUO 2017: Oncologic Outcomes Comparing Open and Robot-Assisted Laparoscopic Radical Cystectomy for Bladder Cancer
Washington, DC (UroToday.com) Dr. Marzouk and colleagues from Memorial Sloan Kettering Cancer Center reported oncological outcomes from their randomized control trial (RCT) comparing open (ORC) to robotic radical cystectomy (RARC). The authors previously reported the primary endpoints evaluating perioperative outcomes for ORC vs RARC1 demonstrating no advantage for robotic-assisted techniques over standard open surgery with regards to 90-day complication rates, length of hospital stay, and 3- and 6-month quality of life outcomes. The objective of this study was to report secondary endpoints of cancer specific outcomes from this prospective, randomized trial comparing RARC vs ORC.
SUO 2017: Inaccuracy of Clinical Staging After Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Washington, DC (UroToday.com) Dr. Meyer and colleagues presented their work assessing inaccuracy of clinical staging after neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). Based on randomized clinical trial data1, the standard of care for patients with MIBC is radical cystectomy (RC) + neoadjuvant chemotherapy (NAC). The authors report that they routinely perform restaging workup post-NAC prior to RC including imaging and cystoscopy with resection/biopsy. The objective of the current study was to evaluate the accuracy of restaging after NAC by comparing post-NAC with final RC pathology.
SUO 2017: Chemotherapy Prior to Radical Nephroureterectomy in Patients with Advanced Upper Tract Urothelial Carcinoma
Washington, DC (UroToday.com) Dr. Miest and colleagues presented their institutional experience of chemotherapy prior to radical nephroureterectomy for patients with advanced upper tract urothelial carcinoma (UTUC). Although chemotherapy improves survival in muscle-invasive urothelial carcinoma of the bladder, its use in the management of UTUC either before or after radical nephroureterectomy remains unclear. The objective of this study was to determine the outcomes of neoadjuvant chemotherapy in patients with UTUC.